InvestorsObserver
×
News Home

Analyst Rating: Will Cocrystal Pharma Inc (COCP) Stock Outperform the Market?

Thursday, August 12, 2021 10:43 AM | InvestorsObserver Analysts

Mentioned in this article

Analyst Rating: Will Cocrystal Pharma Inc (COCP) Stock Outperform the Market?

Wall Street is positive on Cocrystal Pharma Inc (COCP). On average, analysts give COCP a Strong Buy rating. The average price target is $4.5, which means analysts expect the stock to increase by 324.53% over the next twelve months. That average ranking earns COCP an Analyst Rating of 75, which is better than 75% of stocks based on data compiled by InvestorsObserver.

Overall Score - 5
Wall Street analysts are rating COCP a Strong Buy today. Find out what this means to you and get the rest of the rankings on COCP!

Why are Analyst Ratings Important?

A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement. InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.

What's Happening With Cocrystal Pharma Inc Stock Today?

Cocrystal Pharma Inc (COCP) stock is unmoved 0% while the S&P 500 is lower by -0.08% as of 10:39 AM on Thursday, Aug 12. COCP is flat $0.00 from the previous closing price of $1.06 on volume of 218,176 shares. Over the past year the S&P 500 has gained 31.47% while COCP is lower by -47.00%. COCP lost -$0.17 per share the over the last 12 months. Click Here to get the full Stock Report for Cocrystal Pharma Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App